EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modifications of the Prothrombin Active Site S4 Subpocket Confer Resistance to Dabigatran

Viola J F Strijbis iD, Ka Lei Cheung, Dejvid Veizaj iD, Tessa Rutten, Boris de Bruin, Pieter H Reitsma, Daniël Verhoef iD, Mettine H A Bos iD

Thrombosis and Haemostasis · 01.01.2026 · 126 (01) · 023-036

DOI: 10.1055/a-2537-6037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.01.2026. Verfasst von Viola J F Strijbis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden Universit…. Hauptthemen laut MEDLINE: Dabigatran, Prothrombin, Antithrombins, Drug Resistance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health~Holland, Top Sector Life Sciences & Health, Health∼Holland, Top Sector Life Sciences & Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Direct anticoagulants inhibit coagulation serine proteases by reversibly engaging their active site with high affinity. By modifying the S4 active site subpocket of factor (F)Xa, we introduced inhibitor resistance while preserving catalytic activity. Given the homology between FXa and thrombin in active site architecture and direct anticoagulant binding, we have targeted the S4 subsite to introduce inhibitor resistance in (pro)thrombin. Recombinant prothrombin variants were generated in which I174 was substituted or sequence R92-N98 was exchanged with that of human kallikrein-3. Specific prothrombin clotting activity of the variants was 6-fold (intrinsic clotting) to 10-fold (extrinsic clotting) reduced relative to wild-type prothrombin. Further analyses revealed that modification of the S4 subsite hampers fibrinogen and thrombomodulin-mediated protein C conversion by thrombin. Consistent with this, the thrombin variants displayed a reduced catalytic efficiency toward the peptidyl substrate used in thrombin generation assessments. The variants displayed a 2-fold reduced sensitivity for dabigatran relative to wild-type prothrombin, while argatroban inhibition was unaffected. Analyses using a purified component system revealed an up to 24-fold and 4-fold reduced IC50 for inhibition of thrombin by dabigatran and argatroban, respectively. Molecular dynamics (MD) simulations of both dabigatran-bound and unbound (apo) modified thrombin variants indicated these to comprise a larger inhibitor binding pocket relative to wild-type thrombin and display reduced inhibitor binding. As a net effect, (pro)thrombin variants with S4 subsite modifications supported detectable fibrin formation at therapeutic dabigatran concentrations. Our findings provide proof-of-concept for the engineering of thrombin variants that are resistant to direct thrombin inhibitors by modulating the S4 subsite.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DabigatranProthrombinAntithrombinsDrug ResistanceHumansCatalytic DomainThrombinBlood CoagulationRecombinant ProteinsKallikreinsMolecular Dynamics Simulation

Substanzen

DabigatranProthrombinAntithrombinsThrombinRecombinant ProteinsKallikreins

Autor:innen und Institutionen

  • Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  • VarmX B.V., Leiden, The Netherlands.

ORCID-Profile: Viola J F Strijbis, Dejvid Veizaj, Daniël Verhoef, Mettine H A Bos

Förderung

  • Health~Holland, Top Sector Life Sciences & Health
  • Health∼Holland, Top Sector Life Sciences & Health

Zitieren

APA

Strijbis, V. J. F., Cheung, K. L., Veizaj, D., Rutten, T., de Bruin, B., Reitsma, P. H., Verhoef, D., & Bos, M. H. A. (2026). Modifications of the Prothrombin Active Site S4 Subpocket Confer Resistance to Dabigatran. Thrombosis and Haemostasis, 126(01), 023-036. https://doi.org/10.1055/a-2537-6037

Vancouver

Strijbis VJF, Cheung KL, Veizaj D, Rutten T, de Bruin B, Reitsma PH, et al. Modifications of the Prothrombin Active Site S4 Subpocket Confer Resistance to Dabigatran. Thrombosis and Haemostasis. 2026;126(01):023-036. doi:10.1055/a-2537-6037

BibTeX
@article{Strijbis2026,
  author = {Strijbis, Viola J F and Cheung, Ka Lei and Veizaj, Dejvid and Rutten, Tessa and de Bruin, Boris and Reitsma, Pieter H and Verhoef, Daniël and Bos, Mettine H A},
  title = {Modifications of the Prothrombin Active Site S4 Subpocket Confer Resistance to Dabigatran},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {01},
  pages = {023--036},
  doi = {10.1055/a-2537-6037}
}
Kostenlos starten →